Retrovirus-mediated transfer of human alpha-galactosidase A gene to human CD34+ hematopoietic progenitor cells.

Abstract:

:Fabry disease, caused by a deficiency of lysosomal enzyme alpha-galactosidase A (alpha-gal A), is one of the inherited disorders potentially treatable by gene transfer to hematopoietic stem cells. In this study, a high-titer amphotropic retroviral producer cell line, MFG-alpha-gal A, was established. CD34+ cells from normal umbilical cord blood were transduced by centrifugal enhancement. The alpha-gal A activity in transduced cells increased 3.6-fold above the activity in nontransduced cells. Transduction efficiency measured by PCR for the integrated alpha-gal A cDNA in CFU-GM colonies was in the range of 42-88% (average, 63%). The expression of functional enzyme in TFI erythroleukemia was sustained for as long as cells remained in culture (84 days) and for 28 days in LTC-IC cultures of CD34+ cells. The ability of the transduced CD34+ cells to secrete the enzyme and to correct enzyme-deficient Fabry fibroblasts was assessed by cocultivation of these cells. The enzyme was secreted into the medium from transduced CD34+ cells and taken up by Fabry fibroblasts through mannose 6-phosphate receptors. These findings suggest that genetically corrected hematopoietic stem/progenitor cells can be an enzymatic source for neighboring enzyme-deficient cells, and can potentially be useful for gene therapy of Fabry disease.

journal_name

Hum Gene Ther

journal_title

Human gene therapy

authors

Takiyama N,Dunigan JT,Vallor MJ,Kase R,Sakuraba H,Barranger JA

doi

10.1089/10430349950016302

keywords:

subject

Has Abstract

pub_date

1999-12-10 00:00:00

pages

2881-9

issue

18

eissn

1043-0342

issn

1557-7422

journal_volume

10

pub_type

杂志文章
  • Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium.

    abstract::A phase I clinical trial was conducted in which recombinant adenovirus containing the cystic fibrosis trans-membrane regulator (CFTR) (Ad2/CFTR) was administered by bronchoscopic instillation or aerosolization to the lungs of cystic fibrosis (CF) patients. In this paper, we evaluate the efficiency of Ad2/CFTR-mediated...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1089/104303401750298544

    authors: Perricone MA,Morris JE,Pavelka K,Plog MS,O'Sullivan BP,Joseph PM,Dorkin H,Lapey A,Balfour R,Meeker DP,Smith AE,Wadsworth SC,St George JA

    更新日期:2001-07-20 00:00:00

  • Insulin Therapy Improves Adeno-Associated Virus Transduction of Liver and Skeletal Muscle in Mice and Cultured Cells.

    abstract::Adeno-associated virus (AAV) gene transfer is a promising treatment for genetic abnormalities. Optimal AAV vectors are showing success in clinical trials. Gene transfer to skeletal muscle and liver is being explored as a potential therapy for some conditions, that is, α1-antitrypsin (AAT) disorder and hemophilia B. Ex...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2016.073

    authors: Carrig S,Bijjiga E,Wopat MJ,Martino AT

    更新日期:2016-11-01 00:00:00

  • Efficiency of high- and low-voltage pulse combinations for gene electrotransfer in muscle, liver, tumor, and skin.

    abstract::Gene electrotransfer is gaining momentum as an efficient methodology for nonviral gene transfer. In skeletal muscle, data suggest that electric pulses play two roles: structurally permeabilizing the muscle fibers and electrophoretically supporting the migration of DNA toward or across the permeabilized membrane. To in...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hgt.2008.060

    authors: André FM,Gehl J,Sersa G,Préat V,Hojman P,Eriksen J,Golzio M,Cemazar M,Pavselj N,Rols MP,Miklavcic D,Neumann E,Teissié J,Mir LM

    更新日期:2008-11-01 00:00:00

  • Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.

    abstract::Newcastle disease virus (NDV) is a naturally oncolytic virus that has been shown to be safe and effective for cancer therapy. Tumor virotherapy using NDV emerged in the 1950s and has advanced more recently by the increased availability of reverse genetics technology. In this study, we constructed a reverse genetics sy...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2011.207

    authors: Wei D,Sun N,Nan G,Wang Y,Liu HQ,Peeters B,Chen ZN,Bian H

    更新日期:2012-07-01 00:00:00

  • Gene Editing for Treatment and Prevention of Human Diseases: A Global Survey of Gene Editing-Related Researchers.

    abstract::In the next decades, gene editing technologies are expected to be used in the treatment and prevention of human diseases. Yet, the future uses of gene editing in medicine are still unknown, including its applicability and effectiveness to the treatment and prevention of infectious diseases, cancer, and monogenic and p...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2020.136

    authors: Rocha LFM,Braga LAM,Mota FB

    更新日期:2020-08-01 00:00:00

  • Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.

    abstract::Although recombinant adeno-associated virus serotype 8 (AAV8) and serotype 5 (AAV5) vectors have shown efficacy in Phase 1 clinical trials for gene therapy of hemophilia B, it has become increasingly clear that these serotypes are not optimal for transducing primary human hepatocytes. We have previously reported that ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2020.099

    authors: Brown HC,Doering CB,Herzog RW,Ling C,Markusic DM,Spencer HT,Srivastava A,Srivastava A

    更新日期:2020-10-01 00:00:00

  • CRISPR/Cas9 Editing: Sparking Discussion on Safety in Light of the Need for New Therapeutics.

    abstract::Recent advances in genome sequencing have greatly improved our ability to understand and identify the causes of genetic diseases. However, there remains an urgent need for innovative, safe, and effective treatments for these diseases. CRISPR-based genome editing systems have become important and powerful tools in the ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2020.111

    authors: Carlaw TM,Zhang LH,Ross CJD

    更新日期:2020-08-01 00:00:00

  • Treating Cystic Fibrosis with mRNA and CRISPR.

    abstract::Less than 20% of the protein coding genome is thought to be targetable using small molecules. mRNA therapies are not limited in the same way since in theory, they can silence or edit any gene by encoding CRISPR nucleases, or alternatively, produce any missing protein. Yet not all mRNA therapies are equally likely to s...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2020.137

    authors: Da Silva Sanchez A,Paunovska K,Cristian A,Dahlman JE

    更新日期:2020-09-01 00:00:00

  • Bone Marrow Mesenchymal Stem Cells-Derived Exosomal MicroRNA-150-3p Promotes Osteoblast Proliferation and Differentiation in Osteoporosis.

    abstract::At present, much more studies have focused on the role of microRNAs in osteoporosis, but the more specific role of microRNA-150-3p (miR-150-3p) in osteoporosis still needs full exploration. We aim at investigating the role of miR-150-3p in osteoporosis and at exploring the related mechanisms. Bone marrow mesenchymal s...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2020.005

    authors: Qiu M,Zhai S,Fu Q,Liu D

    更新日期:2021-01-22 00:00:00

  • Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid.

    abstract::Peritoneal compartmentalization of advanced stage ovarian cancer provides a rational scenario for gene therapy strategies. Several groups are exploring intraperitoneal administration of adenoviral (Ad) vectors for this purpose. We examined in vitro gene transfer in the presence of ascites fluid from ovarian cancer pat...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340050111313

    authors: Blackwell JL,Li H,Gomez-Navarro J,Dmitriev I,Krasnykh V,Richter CA,Shaw DR,Alvarez RD,Curiel DT,Strong TV

    更新日期:2000-08-10 00:00:00

  • Neonatal transfer of membrane-bound stem cell factor improves survival and heart function in aged mice after myocardial ischemia.

    abstract::Stem cell mobilization to injured tissue contributes to neovascularization, resulting in regeneration after myocardial infarction (MI). We previously showed that direct cardiac injection of a recombinant lentivirus (LV) that engineers expression of membrane-bound stem cell factor (mSCF) improves outcomes immediately a...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2012.063

    authors: Sun Z,Lee CJ,Mejia-Guerrero S,Zhang Y,Higuchi K,Li RK,Medin JA

    更新日期:2012-12-01 00:00:00

  • Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor.

    abstract::The therapeutic use of neurotrophic factors for neurodegenerative diseases is promising, however, optimal methods for continuous delivery of these substances to the human central nervous system (CNS) remains problematic. One approach would be to graft genetically engineered human cells that continuously secrete high l...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.3-331

    authors: Lin Q,Cunningham LA,Epstein LG,Pechan PA,Short MP,Fleet C,Bohn MC

    更新日期:1997-02-10 00:00:00

  • Assessment of AAV Vector Tropisms for Mouse and Human Pluripotent Stem Cell-Derived RPE and Photoreceptor Cells.

    abstract::Adeno-associated viral vectors are showing great promise as gene therapy vectors for a wide range of retinal disorders. To date, evaluation of therapeutic approaches has depended almost exclusively on the use of animal models. With recent advances in human stem cell technology, stem cell-derived retina now offers the ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2018.027

    authors: Gonzalez-Cordero A,Goh D,Kruczek K,Naeem A,Fernando M,Kleine Holthaus SM,Takaaki M,Blackford SJI,Kloc M,Agundez L,Sampson RD,Borooah S,Ovando-Roche P,Mehat MS,West EL,Smith AJ,Pearson RA,Ali RR

    更新日期:2018-10-01 00:00:00

  • Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field.

    abstract::The field of adenovirology is undergoing rapid change in response to increasing appreciation of the potential advantages of adenoviruses as the basis for new vaccines and as vectors for gene and cancer therapy. Substantial knowledge and understanding of adenoviruses at a molecular level has made their manipulation for...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2013.235

    authors: Majhen D,Calderon H,Chandra N,Fajardo CA,Rajan A,Alemany R,Custers J

    更新日期:2014-04-01 00:00:00

  • Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon.

    abstract::Direct arterial gene transfer has been previously achieved using double-balloon catheters and perforated balloons, in most cases facilitated by the use of cationic liposomes or viral vectors. These gene delivery systems, however, have been compromised by issues relating to efficacy and/or safety, and furthermore requi...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1993.4.6-749

    authors: Riessen R,Rahimizadeh H,Blessing E,Takeshita S,Barry JJ,Isner JM

    更新日期:1993-12-01 00:00:00

  • Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery.

    abstract::Duchenne muscular dystrophy (DMD) is a lethal genetic disorder for which there is currently no effective treatment. Although clinical application of adenoviral vector-mediated gene transfer has not been fully developed, it shows promise for the treatment of DMD. One significant problem posed by adenoviral vector-media...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1995.6.11-1477

    authors: Clemens PR,Krause TL,Chan S,Korb KE,Graham FL,Caskey CT

    更新日期:1995-11-01 00:00:00

  • Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma.

    abstract::The purpose of this study was to determine the safety and antitumor activity of IFN-gamma retroviral vector in patients with advanced melanoma. Seventeen patients (9 single courses, 8 multiple courses) received a total of 363 intratumor injections of IFN-gamma retroviral vector (1 x 10(7) PFU/ml administered at 0.3, 0...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章

    doi:10.1089/10430349950017978

    authors: Nemunaitis J,Fong T,Burrows F,Bruce J,Peters G,Ognoskie N,Meyer W,Wynne D,Kerr R,Pippen J,Oldham F,Ando D

    更新日期:1999-05-20 00:00:00

  • IL-6 production by retrovirus packaging cells and cultured bone marrow cells.

    abstract::Retrovirus integration into the host cell genome occurs most efficiently in replicating cells. In agreement with this notion, it was observed that the efficiency with which hemopoietic stem cells (HSC) can be transduced is greatly enhanced when the hemopoietic growth factor (HGF) interleukin 3 (IL-3) is added to co-cu...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1991.2.4-301

    authors: Einerhand MP,Bakx TA,Valerio D

    更新日期:1991-01-01 00:00:00

  • Engineered U7 Small Nuclear RNA Restores Correct β-Globin Pre-mRNA Splicing in Mouse βIVS2-654-Thalassemic Erythroid Progenitor Cells.

    abstract::Restoration of correct splicing of βIVS2-654-globin pre-mRNA was previously accomplished in erythroid cells from β-thalassemia/HbE patients by an engineered U7 small nuclear RNA (snRNA) that carried a sequence targeted to the cryptic branch point and an exonic splicing enhancer, U7.BP+623 snRNA. In this study, this ap...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2020.145

    authors: d'Arqom A,Nualkaew T,Jearawiriyapaisarn N,Kole R,Svasti S

    更新日期:2020-11-02 00:00:00

  • Highly efficient adenovirus-mediated gene transfer to cardiac myocytes after single-pass coronary delivery.

    abstract::Efficient and homogeneous gene transfer to cardiac myocytes is a major target in myocardial gene therapy. The aim of this study was to determine the conditions permitting efficient, homogeneous, adenovirus-mediated gene transfer to cardiac myocytes, with a view to application during coronary artery catheterization. Ge...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340050015329

    authors: Logeart D,Hatem SN,Rücker-Martin C,Chossat N,Névo N,Haddada H,Heimburger M,Perricaudet M,Mercadier JJ

    更新日期:2000-05-01 00:00:00

  • Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy.

    abstract::Combining chemotherapy and immunotherapy is problematic because chemotherapy can ablate the immune responses initiated by modulators of the immune system. We hypothesized that protection of immunocompetent cells from the toxic effects of chemotherapy, using drug resistance gene therapy strategies, would allow the comb...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.17.798

    authors: McMillin DW,Hewes B,Gangadharan B,Archer DR,Mittler RS,Spencer HT

    更新日期:2006-08-01 00:00:00

  • Cationic phosphonolipids as nonviral gene transfer agents in the lungs of mice.

    abstract::With the aim of developing new gene transfer tools for treating CF with gene therapy, we have synthesized a novel family of molecules named cationic phosphonolipids. The most efficient among them were selected by in vitro screening to compare their activities in vivo in mouse lungs. We used a reporter gene whose activ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.16-2309

    authors: Guillaume-Gable C,Floch V,Mercier B,Audrézet MP,Gobin E,Le Bolch G,Yaouanc JJ,Clément JC,des Abbayes H,Leroy JP,Morin V,Férec C

    更新日期:1998-11-01 00:00:00

  • Reciprocal enhancement of gene transfer by combinatorial adenovirus transduction and plasmid DNA transfection in vitro and in vivo.

    abstract::The addition of replication-defective recombinant adenovirus to plasmid transfection (termed here "adenofection") has been shown to increase plasmid transgene expression in limited studies. Similarly, the addition of cationic liposomes to adenovirus increases adenovirus-mediated gene transduction (termed here "lipoduc...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950017059

    authors: Dunphy EJ,Redman RA,Herweijer H,Cripe TP

    更新日期:1999-09-20 00:00:00

  • Endothelial Progenitor Cells as Shuttle of Anticancer Agents.

    abstract::Cell therapies are treatments in which stem or progenitor cells are stimulated to differentiate into specialized cells able to home to and repair damaged tissues. After their discovery, endothelial progenitor cells (EPCs) stimulated worldwide interest as possible vehicles to perform autologous cell therapy of tumors. ...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2016.066

    authors: Laurenzana A,Margheri F,Chillà A,Biagioni A,Margheri G,Calorini L,Fibbi G,Del Rosso M

    更新日期:2016-10-01 00:00:00

  • Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.

    abstract::Genetically modified lymphoblastoid cell lines (LCL) have been shown to be an attractive alternative source of antigen-presenting cells for cancer vaccination in vitro. We tested their application in patients with pancreatic cancer in a phase I clinical trial. As a model tumor antigen, we selected the point-mutated (c...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章

    doi:10.1089/hum.2011.153

    authors: Kubuschok B,Pfreundschuh M,Breit R,Hartmann F,Sester M,Gärtner B,König J,Murawski N,Held G,Zwick C,Neumann F

    更新日期:2012-12-01 00:00:00

  • Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage.

    abstract::Successful gene transfer into articular cartilage is a prerequisite for gene therapy of articular joint disorders. In the present study we tested the hypothesis that recombinant adeno-associated virus (rAAV) vectors are capable of effecting gene transfer in isolated articular chondrocytes in vitro, articular cartilage...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303403321208998

    authors: Madry H,Cucchiarini M,Terwilliger EF,Trippel SB

    更新日期:2003-03-01 00:00:00

  • Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy.

    abstract::Mutations in the gene encoding the peroxisomal ATP-binding cassette transporter (ABCD1) cause elevations in very long-chain fatty acids (VLCFAs) and the neurodegenerative disease adrenoleukodystrophy (ALD). In most adults, this manifests as the spinal cord axonopathy adrenomyeloneuropathy (AMN). A challenge in virus-b...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2018.079

    authors: Gong Y,Berenson A,Laheji F,Gao G,Wang D,Ng C,Volak A,Kok R,Kreouzis V,Dijkstra IM,Kemp S,Maguire CA,Eichler F

    更新日期:2019-05-01 00:00:00

  • Gene therapy for oxidant injury-related diseases: adenovirus-mediated transfer of superoxide dismutase and catalase cDNAs protects against hyperoxia but not against ischemia-reperfusion lung injury.

    abstract::Hyperoxia and ischemia-reperfusion cause profound lung cellular damage mediated, in part, by generation of oxygen radicals. We hypothesized that gene therapy can be used to overcome oxidant injury by augmenting intracellular antioxidant enzymes. Adult rats were injected intratracheally with an adenovirus (Ad) vector e...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.10-1487

    authors: Danel C,Erzurum SC,Prayssac P,Eissa NT,Crystal RG,Hervé P,Baudet B,Mazmanian M,Lemarchand P

    更新日期:1998-07-01 00:00:00

  • A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency.

    abstract::Ornithine transcarbamylase deficiency (OTCD) is an inborn error of urea synthesis that has been considered as a model for liver-directed gene therapy. Current treatment has failed to avert a high mortality or morbidity from hyperammonemic coma. Restoration of enzyme activity in the liver should suffice to normalize me...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340152712719

    authors: Raper SE,Yudkoff M,Chirmule N,Gao GP,Nunes F,Haskal ZJ,Furth EE,Propert KJ,Robinson MB,Magosin S,Simoes H,Speicher L,Hughes J,Tazelaar J,Wivel NA,Wilson JM,Batshaw ML

    更新日期:2002-01-01 00:00:00

  • Pressure-mediated transfection of murine spleen and liver.

    abstract::Extension of in vivo nucleic acid transfection techniques and increased information about those transfection properties and side effects are urgently needed to advance biological research and drug therapy. Tissue pressure-mediated transfection, involving lightly pressing the target tissue after intravenous injection o...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2008.213

    authors: Mukai H,Kawakami S,Kamiya Y,Ma F,Takahashi H,Satake K,Terao K,Kotera H,Yamashita F,Hashida M

    更新日期:2009-10-01 00:00:00